- Molecular NameQuinine
- Synonym6'-Methoxycinchonidine; 6'-Methoxycinchonine; Quinine sulfate; Quinine, Anhydrous; Quinineanhydrous; Quinoline Alkaloid
- Weight324.424
- Drugbank_IDDB00468
- ACS_NO130-95-0
- Show 2D model
- LogP (experiment)3.44
- LogP (predicted, AB/LogP v2.0)2.89
- pka4.1, 8.5
- LogD (pH=7, predicted)1.32
- Solubility (experiment)0.53 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-1.2
- LogSw (predicted, AB/LogsW2.0)0.28
- Sw (mg/ml) (predicted, ACD/Labs)0.15
- No.of HBond Donors1
- No.of HBond Acceptors4
- No.of Rotatable Bonds4
- TPSA45.59
- StatusFDA approved
- AdministrationOral, intravenous
- PharmacologyA natural white crystalline alkaloid having antipyretic (fever-reducing), antimalarial, analgesic (painkilling), and anti-inflammatory properties and a bitter taste. It is a stereoisomer of quinidine.
- Absorption_value85.0
- Absorption (description)N/A
- Caco_2N/A
- Bioavailability76.0
- Protein binding80.0
- Volume of distribution (VD)1.8 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmHepatic (mostly CYP3A4 and CYP2C19-mediated; >80%)
- Half life18 h
- ExcretionRenal (20%)
- Urinary Excretion12~20
- Clerance1.9 ml/min/kg
- ToxicityThe most common adverse events associated with quinine use are a cluster of symptoms called "cinchonism", which occurs to some degree in almost all patients taking quinine. Symptoms of mild cinchonism include headache, vasodilation and sweating, nausea, tinnitus, hearing impairment, vertigo or dizziness, blurred vision, and disturbance in color perception. More severe symptoms of cinchonism are vomiting, diarrhea, abdominal pain, deafness, blindness, and disturbances in cardiac rhythm or conduction. Most symptoms of cinchonism are reversible and resolve with discontinuation of quinine.
- LD50 (rat)N/A
- LD50 (mouse)LD50=207 (ip)